# A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer

> **NCT03048136** · PHASE3 · WITHDRAWN · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03048136
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-03-09
- **Primary completion:** 2019-09-29
- **Final completion:** 2019-09-29
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business objective has changed
- **Last updated:** 2018-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03048136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03048136, "A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03048136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*